Patents by Inventor Bret Marin

Bret Marin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions of activated botulinum holotoxin type B (150 kD)
    Publication number: 20100112006
    Abstract: The present invention relates to pharmaceutical compositions of activated botulinum holotoxin type B (150 kD). In particular, the present invention relates to botulinum toxin type B pharmaceutical compositions wherein at least 90% of said botulinum toxin type B is activated (i.e., “nicked”), and wherein at least 99% said nicked botulinum toxin type B is a 150 kD holotoxin (i.e., “stripped”). The invention also relates to a process of activating and stripping botulinum toxin type B wherein at least 90% of said botulinum toxin type B is nicked, and wherein at least 99% of said nicked botulinum toxin type B is stripped. The invention further relates to methods for the treatment of a variety of neuromuscular diseases, pain, inflammatory and cutaneous disorders comprising administering a pharmaceutical composition of activated botulinum holotoxin type B (150 kD) wherein at least 90% of said botulinum toxin type B is nicked, and wherein at least 99% of said nicked botulinum toxin type B is stripped.
    Type: Application
    Filed: November 3, 2009
    Publication date: May 6, 2010
    Applicant: Solstice Neurosciences, Inc.
    Inventors: Sheryl Ann Garcia, Bret Marin, Shaji Joseph
  • Compositions of activated botulinum toxin type B
    Publication number: 20100112005
    Abstract: The present invention relates to pharmaceutical compositions of activated botulinum toxin type B. In particular, the present invention relates to botulinum toxin type B pharmaceutical compositions wherein at least 90% of said botulinum toxin type B is activated—i.e., “nicked”. The invention also relates to a process of activating botulinum toxin type B wherein at least 90% of said botulinum toxin type B is nicked. The invention further relates to methods for the treatment of a variety of overactive or neuromuscular diseases, pain, inflammatory and cutaneous disorders comprising administering a pharmaceutical composition of activated botulinum toxin type B wherein at least 90% of said botulinum toxin type B is nicked.
    Type: Application
    Filed: November 3, 2009
    Publication date: May 6, 2010
    Applicant: Solstice Neurosciences, Inc.
    Inventors: Sheryl Ann Garcia, Bret Marin, Shaji Joseph
  • Compositions of activated botulinum toxin type B
    Publication number: 20100034853
    Abstract: The present invention relates to pharmaceutical compositions of activated botulinum toxin type B. In particular, the present invention relates to botulinum toxin type B pharmaceutical compositions wherein at least 75% of said botulinum toxin type B is activated—i.e., “nicked”. The invention also relates to a process of activating botulinum toxin type B wherein at least 75% of said botulinum toxin type B is nicked. The invention further relates to methods for the treatment of a variety of neuromuscular diseases, pain, inflammatory and cutaneous disorders comprising administering a pharmaceutical composition of activated botulinum toxin type B wherein at least 75% of said botulinum toxin type B is nicked.
    Type: Application
    Filed: August 4, 2009
    Publication date: February 11, 2010
    Applicant: Solstice Neurosciences, Inc.
    Inventors: Sheryl Ann Garcia, Bret Marin, Shaji Joseph
  • Compositions of activated botulinum holotoxin type B (150 KD)
    Publication number: 20100034854
    Abstract: The present invention relates to pharmaceutical compositions of activated botulinum holotoxin type B (150 kD). In particular, the present invention relates to botulinum toxin type B pharmaceutical compositions wherein at least 75% of said botulinum toxin type B is activated (i.e., “nicked”), and wherein at least 75% said nicked botulinum toxin type B is a 150 kD holotoxin (i.e., “stripped”). The invention also relates to a process of activating and stripping botulinum toxin type B wherein at least 75% of said botulinum toxin type B is nicked, and wherein at least 75% of said nicked botulinum toxin type B is stripped. The invention further relates to methods for the treatment of a variety of neuromuscular diseases, pain, inflammatory and cutaneous disorders comprising administering a pharmaceutical composition of activated botulinum holotoxin type B (150 kD) wherein at least 75% of said botulinum toxin type B is nicked, and wherein at least 75% of said nicked botulinum toxin type B is stripped.
    Type: Application
    Filed: August 4, 2009
    Publication date: February 11, 2010
    Applicant: Solstice Neurosciences, Inc.
    Inventors: Sheryl Ann Garcia, Bret Marin, Shaji Joseph